Exploratory analysis of a phase 3 trial in lower-risk MDS with transfusion-dependent anaemia: fewer imetelstat-treated patients had worsening fatigue and more had sustained fatigue and quality-of-life improvement vs placebo (nominal P values).
Secondary analysis
Sekeres et al. Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study